We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: SeaSpine Holdings Corporation is a medical technology company which focused on the design, development and commercialization of surgical solutions for the treatment of spinal disorders. The company also offers orthobiologics and spinal fusion hardware solutions. SeaSpine Holdings Corporation is headquartered in Vista, California.
- Recent SPNE Stock Price: $5.74
- Yearly Gain for SPNE stock: -71.04%
- Market Cap for SPNE stock: $218.59M
- P/E Ratio for SPNE stock: -3.697
Will SPNE's stock price go up? Is there an accurate SPNE stock forecast available?
TipRanks.com reports that SeaSpine Holdings currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $19.00. The target pricing ranges from a high SPNE forecast of $21.00 down to a low forecast of $16.00. SeaSpine Holdings (SPNE)’s last closing stock price was $5.74 which would put the average price target at 231.01% upside.
In addition, TradingView issued a Strong Sell rating for SPNE stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on SPNE stock.
Other analysts covering SPNE include:
- Ross Osborn of Cantor Fitzgerald issued a Buy rating with the price target of n/a on 1 week ago
- Mathew Blackman of Stifel Nicolaus issued a Buy rating with the price target of $ 16 on 1 month ago
- Matthew O'Brien of Piper Sandler issued a Buy rating with the price target of $ 21 on 1 month ago
- Richard Newitter of Truist Financial issued a Buy rating with the price target of $ 20 on 2 months ago
If you are wondering if SPNE is a good stock to buy, here are 3rd party ratings for SPNE stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 36% (161 out of 250)
What is the sentiment on the street regarding SeaSpine Holdings? (Current ratings compiled by TipRanks.com)
- News Sentiment for SPNE stock: Neutral
- Blogger Consensus for SPNE stock: Bullish
- Media Buzz for SPNE stock: Low
- Insider Signal for SPNE stock: ―
- Investor Sentiment for SPNE stock: Very Positive
- Hedge Fund signal for SPNE stock: Neutral
The stock market is extremely volatile, and you need to do your own research on SPNE stock including scouring the social networks like SPNE StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SPNE stock chart >>
Summary: Privia Health Group Inc. is a technology-driven, physician enablement company which collaborates with medical groups, health plans and health systems to optimize physician practices, improve patient experiences and reward doctors for delivering high-value care in both in-person and virtual settings. Privia Health Group Inc. is based in Arlington, United States.
- Recent PRVA Stock Price: $29.66
- Yearly Gain for PRVA stock: -34.51%
- Market Cap for PRVA stock: $3.16B
- P/E Ratio for PRVA stock: -14.59
Will PRVA's stock price go up? Is there an accurate PRVA stock forecast available?
TipRanks.com reports that Privia Health Group currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $34.43. The target pricing ranges from a high PRVA forecast of $40.00 down to a low forecast of $27.00. Privia Health Group (PRVA)’s last closing stock price was $29.66 which would put the average price target at 16.08% upside.
In addition, TradingView issued a Buy rating for PRVA stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on PRVA stock.
Other analysts covering PRVA include:
- Brian Tanquilut of Jefferies issued a Buy rating with the price target of $ 33 on 3 weeks ago
- Lisa Gill of J.P. Morgan issued a Buy rating with the price target of $ 40 on 1 month ago
- A.J. Rice of Credit Suisse issued a Buy rating with the price target of $ 33 on 1 month ago
- David Larsen of BTIG issued a Buy rating with the price target of $ 35 on 1 month ago
If you are wondering if PRVA is a good stock to buy, here are 3rd party ratings for PRVA stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 43% (143 out of 250)
What is the sentiment on the street regarding Privia Health Group? (Current ratings compiled by TipRanks.com)
- News Sentiment for PRVA stock: Very Bullish
- Blogger Consensus for PRVA stock: ―
- Media Buzz for PRVA stock: Low
- Insider Signal for PRVA stock: Positive
- Investor Sentiment for PRVA stock: Very Positive
- Hedge Fund signal for PRVA stock: No Signal
The stock market is extremely volatile, and you need to do your own research on PRVA stock including scouring the social networks like PRVA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for PRVA stock chart >>
Summary: Comera Life Sciences Inc. is involved in developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience. Comera Life Sciences Inc., formerly known as OTR Acquisition Corp., is based in WOBURN, Mass.
- Recent CMRA Stock Price: $2.69
- Yearly Gain for CMRA stock: -73.50%
- Market Cap for CMRA stock: $77.12M
- P/E Ratio for CMRA stock: 15.501
Will CMRA's stock price go up? Is there an accurate CMRA stock forecast available?
TipRanks.com reports that Comera Life Sciences Holdings currently has n/a analysts offering 12-month price targets and the consensus is a rating with an average price target is n/a. The target pricing ranges from a high CMRA forecast of n/a down to a low forecast of n/a. Comera Life Sciences Holdings (CMRA)’s last closing stock price was $2.69 which would put the average price target at upside.
In addition, TradingView issued a Sell rating for CMRA stock over the next month, Barchart.com has a n/a rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CMRA stock.
Other analysts covering CMRA include:
- n/a of n/a issued a n/a rating with the price target of n/a on n/a
- n/a of n/a issued a n/a rating with the price target of n/a on n/a
- n/a of n/a issued a n/a rating with the price target of n/a on n/a
- n/a of n/a issued a n/a rating with the price target of n/a on n/a
If you are wondering if CMRA is a good stock to buy, here are 3rd party ratings for CMRA stock:
- TipRanks.com:
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding Comera Life Sciences Holdings? (Current ratings compiled by TipRanks.com)
- News Sentiment for CMRA stock: ―
- Blogger Consensus for CMRA stock: ―
- Media Buzz for CMRA stock: ―
- Insider Signal for CMRA stock: ―
- Investor Sentiment for CMRA stock: ―
- Hedge Fund signal for CMRA stock: Neutral
The stock market is extremely volatile, and you need to do your own research on CMRA stock including scouring the social networks like CMRA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CMRA stock chart >>
Summary: Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.
- Recent ALT Stock Price: $11.68
- Yearly Gain for ALT stock: 19.49%
- Market Cap for ALT stock: $508.69M
- P/E Ratio for ALT stock: -4.853
Will ALT's stock price go up? Is there an accurate ALT stock forecast available?
TipRanks.com reports that Altimmune currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $21.00. The target pricing ranges from a high ALT forecast of $25.00 down to a low forecast of $12.00. Altimmune (ALT)’s last closing stock price was $11.68 which would put the average price target at 79.79% upside.
In addition, TradingView issued a Buy rating for ALT stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ALT stock.
Other analysts covering ALT include:
- Mayank Mamtani of B.Riley Financial issued a Buy rating with the price target of $ 21 on 6 days ago
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $ 25 on 1 month ago
- Patrick Trucchio of H.C. Wainwright issued a Buy rating with the price target of $ 25 on 1 month ago
- Liisa Bayko of Evercore ISI issued a Buy rating with the price target of $ 12 on 1 month ago
If you are wondering if ALT is a good stock to buy, here are 3rd party ratings for ALT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Buy, Bottom 43% (142 out of 250)
What is the sentiment on the street regarding Altimmune? (Current ratings compiled by TipRanks.com)
- News Sentiment for ALT stock: Very Bullish
- Blogger Consensus for ALT stock: Bullish
- Media Buzz for ALT stock: Low
- Insider Signal for ALT stock: Positive
- Investor Sentiment for ALT stock: Very Positive
- Hedge Fund signal for ALT stock: Positive
The stock market is extremely volatile, and you need to do your own research on ALT stock including scouring the social networks like ALT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ALT stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================